Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Steve Wedge

Newcastle AuthorsTitleYearFull text
Dr Celine Cano
Professor Jane Endicott
Dr Ian Hardcastle
Dr Claire Jennings
Suzanne Kyle
et al.		Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile2024
Dr Elaine Willmore
Suzanne Kyle
Dr Yan Zhao
Huw Thomas
Dr Kenneth Rankin
et al.		Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index2024
Professor Gareth Veal
Professor Steve Wedge
Dr Christopher Bacon
Professor Philip Sloan
Professor Alastair Greystoke
et al.		A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer2023
Dr Catherine Salvini
Benoit Darlot
Jack Davison
Dr Mathew Martin
Dr Susan Tudhope
et al.		Fragment expansion with NUDELs – poised DNA-encoded libraries2023
Duncan Miller
Dr Suzannah Harnor
Dr Mathew Martin
Dr Richard Noble
Professor Steve Wedge
et al.		Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy2023
Dr Nahoum Anthony
Charlotte Jennings
Dr Mathew Martin
Dr Richard Noble
Nicole Phillips
et al.		Targeting cytotoxic agents through EGFR-mediated covalent binding and release2023
Duncan Miller
Tristan Reuillon
Dr Lauren Molyneux
Dr Tim Blackburn
Dr Noel Edwards
et al.		Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor2022
Dr Richard Noble
Huw Thomas
Dr Yan Zhao
Professor Steve Wedge
Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma2022
Islam Al-Khawaldeh
Dr Christine Basmadjian
Dr Cinzia Bordoni
Dr Suzannah Harnor
Amy Heptinstall
et al.		An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)2021
Dr Ian Hardcastle
Dr Ruth Bawn
Dr Tim Blackburn
Dr Celine Cano
Dr Sarah Cully
et al.		Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction2021
John Moir
Anna Long
Dr Beate Haugk
Jeremy French
Richard Charnley
et al.		Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer2020
Stephanie Myers
Duncan Miller
Dr Lauren Molyneux
Dr Mercedeh Arasta
Dr Ruth Bawn
et al.		Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD42019
Dr Catherine Willoughby
Huw Thomas
Dr Elaine Willmore
Suzanne Kyle
Dr Anita Wittner
et al.		Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy2019
Professor Ruth Plummer
Professor Steve Wedge
Professor Gareth Veal
A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours2018
Honorine Lebraud
Dr Richard Noble
Nicole Phillips
Dr Yan Zhao
Emeritus Professor Herbie Newell
et al.		A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition2018
123456